Assenagon Asset Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $178M | Sell |
4,173,559
-5,884,377
| -59% | -$320M | 0.22% | 81 |
|
|
2026
Q1 | $631M | Buy |
10,057,936
+5,751,760
| +134% | +$460M | 0.96% | 17 |
|
|
2025
Q4 | $411M | Buy |
4,306,176
+1,391,559
| +48% | +$136M | 0.57% | 31 |
|
|
2025
Q3 | $285M | Buy |
2,914,617
+243,100
| +9% | +$25.2M | 0.39% | 47 |
|
|
2025
Q2 | $287M | Buy |
2,671,517
+185,821
| +7% | +$18.8M | 0.43% | 47 |
|
|
2025
Q1 | $251M | Buy |
2,485,696
+1,536,663
| +162% | +$155M | 0.42% | 40 |
|
|
2024
Q4 | $84.8M | Sell |
949,033
-2,948,084
| -76% | -$260M | 0.14% | 137 |
|
|
2024
Q3 | $327M | Buy |
3,897,117
+951,580
| +32% | +$75M | 0.6% | 26 |
|
|
2024
Q2 | $227M | Sell |
2,945,537
-144,116
| -5% | -$10.5M | 0.51% | 35 |
|
|
2024
Q1 | $212M | Buy |
3,089,653
+1,034,005
| +50% | +$66.5M | 0.5% | 33 |
|
|
2023
Q4 | $119M | Sell |
2,055,648
-1,205,966
| -37% | -$64.4M | 0.32% | 59 |
|
|
2023
Q3 | $172M | Buy |
3,261,614
+146,495
| +5% | +$7.68M | 0.53% | 29 |
|
|
2023
Q2 | $168M | Buy |
3,115,119
+1,182,680
| +61% | +$61.8M | 0.58% | 29 |
|
|
2023
Q1 | $96.7M | Sell |
1,932,439
-534,302
| -22% | -$25.2M | 0.34% | 60 |
|
|
2022
Q4 | $114M | Sell |
2,466,741
-1,291,963
| -34% | -$55.9M | 0.41% | 46 |
|
|
2022
Q3 | $146M | Buy |
3,758,704
+635,016
| +20% | +$25.5M | 0.56% | 34 |
|
|
2022
Q2 | $116M | Buy |
3,123,688
+45,299
| +1% | +$1.84M | 0.43% | 39 |
|
|
2022
Q1 | $136M | Buy |
3,078,389
+1,057,577
| +52% | +$45.8M | 0.38% | 51 |
|
|
2021
Q4 | $85.8M | Sell |
2,020,812
-2,214,905
| -52% | -$93.1M | 0.25% | 71 |
|
|
2021
Q3 | $184M | Buy |
4,235,717
+740,282
| +21% | +$32.8M | 0.59% | 34 |
|
|
2021
Q2 | $149M | Buy |
3,495,435
+101,710
| +3% | +$4.28M | 0.51% | 34 |
|
|
2021
Q1 | $131M | Sell |
3,393,725
-1,901,032
| -36% | -$72M | 0.53% | 34 |
|
|
2020
Q4 | $190M | Buy |
5,294,757
+4,460,713
| +535% | +$161M | 0.83% | 23 |
|
|
2020
Q3 | $31.9M | Buy |
+834,044
| New | +$32.1M | 0.18% | 95 |
|
|
2020
Q2 | – | Sell |
-583,655
| Closed | -$19M | – | 1120 |
|
|
2020
Q1 | $19M | Sell |
583,655
-873,606
| -60% | -$34.1M | 0.15% | 108 |
|
|
2019
Q4 | $65.9M | Buy |
1,457,261
+1,380,055
| +1,787% | +$57.7M | 0.41% | 50 |
|
|
2019
Q3 | $3.14M | Sell |
77,206
-262,052
| -77% | -$11.1M | 0.02% | 318 |
|
|
2019
Q2 | $14.6M | Sell |
339,258
-352,756
| -51% | -$13.6M | 0.11% | 129 |
|
|
2019
Q1 | $26.6M | Buy |
692,014
+617,226
| +825% | +$23.6M | 0.25% | 81 |
|
|
2018
Q4 | $2.64M | Buy |
74,788
+63,682
| +573% | +$2.31M | 0.03% | 371 |
|
|
2018
Q3 | $428K | Sell |
11,106
-248,932
| -96% | -$8.69M | ﹤0.01% | 717 |
|
|
2018
Q2 | $8.5M | Sell |
260,038
-12,624
| -5% | -$381K | 0.1% | 192 |
|
|
2018
Q1 | $7.45M | Sell |
272,662
-164,965
| -38% | -$4.48M | 0.1% | 187 |
|
|
2017
Q4 | $10.8M | Buy |
437,627
+270,488
| +162% | +$7.46M | 0.11% | 169 |
|
|
2017
Q3 | $4.88M | Buy |
167,139
+20,181
| +14% | +$557K | 0.05% | 241 |
|
|
2017
Q2 | $4.07M | Buy |
146,958
+114,194
| +349% | +$3.03M | 0.09% | 93 |
|
|
2017
Q1 | $815K | Sell |
32,764
-1,570,307
| -98% | -$38.2M | 0.02% | 180 |
|
|
2016
Q4 | $34.7M | Buy |
+1,603,071
| New | +$35M | 0.65% | 41 |
|
Other funds holding BSX
Assenagon Asset Management's BSX Position: Q2 2026 in Review
Assenagon Asset Management reduced its Boston Scientific (BSX) stake by 59% in Q2 2026, selling an estimated $320M and leaving 4,173,559 shares worth $178M. The position accounts for 0.22% of the portfolio, ranked #81.
Assenagon Asset Management first reported a position in BSX in Q4 2016 and has held it in 38 quarters since. The position peaked at $631M in Q1 2026. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Assenagon Asset Management held 4,173,559 shares of Boston Scientific worth $178M as of Q2 2026.
- Assenagon Asset Management sold 5,884,377 Boston Scientific shares in Q2 2026, an estimated $320M.
- Boston Scientific made up 0.22% of Assenagon Asset Management's portfolio in Q2 2026, its #81 holding.
- Assenagon Asset Management first reported a position in Boston Scientific in Q4 2016 and has held it in 38 quarters since.
- Assenagon Asset Management's Boston Scientific position peaked at $631M in Q1 2026.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.